EGRX News and Press, Eagle Pharmaceuticals Inc. From 03/13/23

2023-03-13 06:54:27 ET Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q4 Non-GAAP EPS of $1.11 beats by $0.28 . Revenue of $60.7M (+43.4% Y/Y) misses by $3.56M . Q4 2022 RYANODEX net product sales were $7.2 million, compared to $6.1 million in the...

• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share 1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net inco...

2023-03-10 10:16:05 ET Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q4 earnings results on Monday, March 13th, before market open. The consensus EPS Estimate is $0.83 (-2.4% Y/Y) and the consensus Revenue Estimate is $64.26M (+51.8% Y/Y). Over the la...

WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a fireside chat at...

WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the ma...

Summary Among healthcare stocks, Eagle Pharmaceuticals is an interesting opportunity to benefit from volatility in stock markets. Eagle Pharmaceuticals' product portfolio continues to perform well and has the potential to strengthen its position in the market through new treatment devel...

Eagle Pharmaceuticals ( NASDAQ: EGRX ) announced its preliminary guidance for 2023 on Tuesday, indicating $4.20-$4.53 of adjusted non-GAAP earnings per share compared to $4.42 in the consensus. The company also expects its 2022 adj. EBITDA and adj. non-GAAP R&D expenses to reach $...

WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded n...

WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41 st A...

-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamou...